Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 4, 2023Business Wire • 04/24/23
Aurinia Pharmaceuticals Announces New and Refined Method of Use Patent for LUPKYNIS® in the Treatment of Lupus Nephritis Issued by United States Patent and Trademark OfficeBusiness Wire • 04/11/23
Aurinia Pharmaceuticals Announces Promising Topline Data from Renal Biopsy Sub-study of the AURORA TrialBusiness Wire • 04/05/23
Aurinia (AUPH) Surges 11.0%: Is This an Indication of Further Gains?Zacks Investment Research • 03/27/23
Aurinia Reports Fourth Quarter and Full Year 2022 Financial Results and Company UpdatesBusiness Wire • 02/28/23
Aurinia Pharmaceuticals to Present at Upcoming Investor Healthcare ConferenceBusiness Wire • 02/24/23
Aurinia Pharmaceuticals (AUPH) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 02/22/23
Aurinia Pharmaceuticals to Release Fourth Quarter and Full Year Financial and Operational Results on February 28, 2023Business Wire • 02/07/23
Aurinia Pharmaceuticals Announces Allowance of a New and Refined Method of Use Patent for LUPKYNIS® in the Treatment of Lupus Nephritis From the United States Patent and Trademark OfficeBusiness Wire • 01/24/23
Aurinia Provides Preliminary Unaudited Fourth Quarter and Full-year 2022 Net Revenue ResultsBusiness Wire • 01/06/23
Aurinia Pharmaceuticals to Present at Upcoming 41st Annual J.P. Morgan Healthcare ConferenceBusiness Wire • 01/04/23